Rigel AI Stock Analysis
Want to see RIGL full AI Analyst Report?
Rigel (RIGL) AI Stock Analysis
Rigel
(NASDAQ:RIGL)
The score is driven primarily by improved financial performance (profitability, cash generation, and reduced leverage) and strong earnings-call execution/guidance around commercial momentum (notably VEPPANU). This is tempered by weak technicals (bearish trend with negative momentum) and some sustainability questions around unusually high net profitability and rising cost intensity, despite an attractive low P/E valuation.
Rigel (RIGL) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $837.18M
- Dividend Yield
- ―
- Average Volume (3M)
- 255.43K
- Price to Earnings (P/E)
- 2.6
- Beta (1Y)
- 1.61
- Revenue Growth
- 2.18%
- EPS Growth
- 165.65%
- Country
- US
- Employees
- 173
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Rigel Business Overview & Revenue Model
Company Description
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibito...
How the Company Makes Money
Rigel generates revenue primarily from product sales of its marketed therapies and, where applicable, from collaboration- and licensing-related payments. (1) Product revenue: Rigel sells TAVALISSE (fostamatinib) and REZLIDHIA (olutasidenib) in market...
Rigel Earnings Call Summary
The call was strongly positive overall. Rigel reported record quarterly product sales, profitability, broad early adoption and favorable access metrics for the VEPPANU launch, continued growth from TAVALISSE and REZLIDHIA, and progress toward R289's next development stages. These positives outweighed the GAVRETO decline, lower net income, increased costs, reduced cash balance and moderation in expected TAVALISSE growth.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, Rigel updated and narrowed guidance to total revenues in the range of approximately $290 million to $295 million, including approximately $255 million to $260 million in net product sales, excluding VEPPANU, and approximately $35 million in contract revenues, versus previous ranges of $285 million to $295 million, approximately $255 million to $265 million, and previous expectation of approximately $30 million, respectively; the company continues to anticipate reporting positive net income for the full year while funding existing and new clinical development programs and supporting the commercial launch of VEPPANU, plans to complete enrollment and select the recommended Phase 2 dose for R289 by the end of 2026, and is targeting initiating a registration study in 2027.
Rigel Financial Statement Overview
Summary
Financials reflect a strong turnaround with solid profitability and positive operating/free cash flow in 2024–TTM 2026, alongside a significantly de-risked balance sheet and very low current leverage. Constraints are the unusually high net profitability versus revenue in 2025–TTM 2026 (suggesting non-core items may be influencing results) and historical volatility in operating profitability and cash-flow coverage.
Income Statement
78PositiveBalance Sheet
74PositiveCash Flow
71Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 288.21M | 294.28M | 179.28M | 116.88M | 120.24M | 149.24M |
| Gross Profit | 258.34M | 274.66M | 160.63M | 109.77M | 118.49M | 148.15M |
| EBITDA | 83.37M | 131.56M | 28.51M | -16.98M | -53.87M | -11.29M |
| Net Income | 307.19M | 367.02M | 17.48M | -25.09M | -58.57M | -17.91M |
Balance Sheet | ||||||
| Total Assets | 523.88M | 513.59M | 163.98M | 117.22M | 134.28M | 167.33M |
| Cash, Cash Equivalents and Short-Term Investments | 99.31M | 154.96M | 77.32M | 56.93M | 58.21M | 124.97M |
| Total Debt | 7.79M | 53.30M | 59.97M | 60.58M | 41.55M | 30.57M |
| Total Liabilities | 78.77M | 122.11M | 160.69M | 145.87M | 147.90M | 136.95M |
| Stockholders Equity | 445.11M | 391.48M | 3.29M | -28.64M | -13.62M | 30.37M |
Cash Flow | ||||||
| Free Cash Flow | 89.93M | 75.66M | 31.07M | -20.74M | -74.21M | 5.25M |
| Operating Cash Flow | 89.92M | 75.66M | 31.47M | -5.74M | -73.76M | 5.88M |
| Investing Cash Flow | -34.33M | -92.36M | 4.13M | -4.30M | 72.78M | -80.04M |
| Financing Cash Flow | -57.48M | 601.00K | -11.64M | 18.37M | 6.55M | 62.67M |
Rigel Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RIGL, the sentiment is Negative. The current price of 44.46 is below the 20-day moving average (MA) of 47.57, below the 50-day MA of 47.44, and above the 200-day MA of 37.59, indicating a neutral trend. The MACD of -0.98 indicates Positive momentum. The RSI at 44.14 is Neutral, neither overbought nor oversold. The STOCH value of 50.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RIGL.
Rigel Risk Analysis
Rigel disclosed 60 risk factors in its most recent earnings report. Rigel reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksRigel Peers Comparison
Overall Rating
RIGL69Neutral
VSTM54Neutral
RGNX51Neutral
BCYC46Neutral
LXRX46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | $837.18M | 2.64 | 73.94% | ― | 2.18% | 165.65% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | $1.03B | -4.42 | -359.49% | ― | 649.65% | 54.01% | |
| 51Neutral | $505.18M | -2.38 | -203.98% | ― | -4.59% | 8.03% | |
| 46Neutral | $235.88M | -1.66 | -26.02% | ― | 194.79% | 43.93% | |
| 46Neutral | $796.97M | -12.32 | -38.44% | ― | -45.62% | 21.16% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RIGL | Rigel Pharmaceuticals | 44.46 | -1.76 | -3.81% | |
| LXRX | Lexicon Pharmaceuticals | 1.79 | 0.32 | 21.77% | |
| VSTM | Verastem Inc | 8.18 | -1.09 | -11.76% | |
| RGNX | RegenXBio Inc. | 7.64 | -3.61 | -32.09% | |
| BCYC | Bicycle Therapeutics | 3.37 | -3.10 | -47.91% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
